Name (Synonyms) | Correlation |
---|
There is one clinical trial.
To evaluate the safety and efficacy of humanized Meplazumab for Injection in patients infected by 2019-nCoA.
Description: Virological clearance rate using Real-Time PCR in upper and/or lower respiratory tract samples at day 3, day 7 and day 14 respectively.
Measure: 2019 nCoV nucleic acid detection Time: 14 daysDescription: Time (days) from initiation of Meplazumab treatment until normalization of body temperature (≤37℃ axilla)
Measure: Recovery of body temperature Time: 14 daysDescription: Time (days) from initiation of Meplazumab treatment until normalization of resting respiratory rate (≤24/min)
Measure: Recovery of resting respiratory rate Time: 14 daysDescription: Time (days) from initiation of Meplazumab treatment until normalization of SPO2 (>94%)
Measure: Recovery of SPO2 Time: 14 daysDescription: Rate of lung imaging recovery
Measure: Chest CT / chest film changes Time: 28 daysDescription: Rate of PaO2 / FiO2 recovery
Measure: PaO2 / FiO2 Time: 14 daysDescription: Days to reach the isolation release standard
Measure: Time to reach the isolation release standard Time: 28 daysDescription: Rate of CRP, D-Dimer test recovery
Measure: Changes of inflammatory immune status Time: 14 days